Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Aged
Bone Diseases
/ diagnostic imaging
Bone Neoplasms
/ diagnostic imaging
Cohort Studies
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Middle Aged
Oligopeptides
Positron Emission Tomography Computed Tomography
/ methods
Prostatic Neoplasms
/ complications
Retrospective Studies
Ribs
/ diagnostic imaging
#PCSM
#ProstateCancer
PSMA PET/CT
prostate cancer
ribs
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
28
6
2020
medline:
15
1
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
To determine the proportion of solitary rib lesions on pre-treatment This retrospective single tertiary referral institution cohort study of men reviewed the results of A total of 62 men had PSMA uptake in a solitary rib lesion; 54 went on to have RPs and eight underwent RT. In all, 61 of the men (98.4%) met the criteria for a benign rib lesion. Only one man had a false-negative malignant lesion. This man had a rib lesion with a low maximum standardised uptake value (SUV To our knowledge, this is the first cohort study of men with PSMA-avid solitary rib lesions on pre-treatment
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-401Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Han S, Woo S, Kim YJ, Suh CH. Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018; 74: 179-90
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-16
Pyka T, Okamoto S, Dahlbender M et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-21
Scheltema MJ, Chang JI, Stricker PD et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI. BJU Int 2019; 124(Suppl 1): 42-9
Habl G, Straube C, Schiller K et al. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 2017; 17: 361
Yaxley JW, Raveenthiran S, Nouhaud FX et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int 2019; 124: 401-7
Haran C, McBean R, Parsons R, Wong D. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: a retrospective review in a private centre. J Med Imaging Radiat Oncol 2019; 63: 495-99
Afshar-Oromieh A, Holland-Letz T, Giesel FL et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-68
Jochumsen MR, Dias AH, Bouchelouche K. Benign traumatic rib fracture: a potential pitfall on 68Ga-prostate-specific membrane antigen PET/CT for prostate cancer. Clin Nucl Med 2018; 43: 38-40
Panagiotidis E, Paschali A, Giannoula E, Chatzipavlidou V. Rib fractures mimicking bone metastases in 18F-PSMA-1007 PET/CT for prostate cancer. Clin Nucl Med 2019; 44: e46-48
Gykiere P, Goethals L, Everaert H. Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin Nucl Med 2016; 41: e346-7
Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-specific membrane antigen PET/CT: false-positive results due to sarcoidosis? Case Rep Oncol 2016; 9: 457-63
Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med 2015; 40: 897-8
Reale ML, Buttigliero C, Tucci M, Giardino R, Poti C. 68Ga-PSMA uptake in fibrous dysplasia. Clin Nucl Med 2019; 44: e396-7
De Coster L, Sciot R, Everaerts W et al. Fibrous dysplasia mimicking bone metastasis on (68)GA-PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017; 44: 1607-8
Blazak JK, Thomas P. Paget disease: a potential pitfall in PSMA PET for prostate cancer. Clin Nucl Med 2016; 41: 699-700
Sasikumar A, Joy A, Nanabala R, Pillai MR, Hari TA. 68Ga-PSMA PET/CT false-positive tracer uptake in Paget disease. Clin Nucl Med 2016; 41: e454-5
Choi HS, Yoo Ie R, Park HL, Choi EK, Kim SH, Lee WH. Role of (1)(8)F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients. Clin Imaging 2014; 38: 109-14
Rauscher I, Krönke M, König M et al. Matched-pair comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med 2020; 61: 51-7
Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med 2017; 42: 465-6
Tyagi S, Singh SK, Narain TA, Singh H, Kumar R, Vadi SK. Synchronous paraganglioma masquerading as 68Ga-PSMA PET/CT-avid metastasis in carcinoma prostate-how specific is 68Ga-PSMA PET/CT? Clin Nucl Med 2019; 44: e420-2
Artigas C, Otte FX, Lemort M, van Velthoven R, Flamen P. Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET/CT. Clin Nucl Med 2017; 42: 368-70
Probst S, Bladou F, Abikhzer G. Extraosseous extension of aggressive vertebral hemangioma as a potential pitfall on 68Ga-PSMA PET/CT. Clin Nucl Med 2017; 42: 624-5
Sasikumar A, Joy A, Pillai MR, Alex TM, Narayanan G. 68Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med 2017; 42: 446-7
Merrild EH, Baerentzen S, Bouchelouche K, Buus S. Vertebral myeloma mimicking prostatic carcinoma metastasis in 68Ga-PSMA PET/CT. Clin Nucl Med 2017; 42: 790-2
Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M. Image of the month: multifocal 68Ga prostate-specific membrane antigen ligand uptake in the skeleton in a man with both prostate cancer and multiple myeloma. Clin Nucl Med 2017; 42: 547-8
Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392: 2353-66
Ong WL, Koh TL, Lim Joon D et al. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. BJU Int 2019; 124(Suppl 1): 19-30
Dolores-Velazquez R, Lever-Rosas CD, Barrera-Franco JL, Padilla-Rosciano A, Frias-Mendivil M, Parra LD. [Primary benign chest wall tumors: results of surgical treatment] [Article in Spanish]. Cir Cir 2007; 75: 419-24
Jakanani GC, Saifuddin A. Percutaneous image-guided needle biopsy of rib lesions: a retrospective study of diagnostic outcome in 51 cases. Skeletal Radiol 2013; 42: 85-90
Baffour FI, Moynagh MR, Eiken PW et al. Effectiveness and safety of percutaneous CT-guided rib biopsy. J Vasc Interv Radiol 2019; 30: 82-6
Lecouvet FE, Geukens D, Stainier A et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25: 3281-7